Nektar Therapeutics
NKTRNektar Therapeutics (Nektar) is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure o …
© Wikipedia /
Creative Commons CC-BY-SA 3.0
more at Wikipedia
Insider trades and stock quote 2024-2026
All insider trades at Nektar Therapeutics
Subscribe RSS| Date | Type | Ø-Price | Volume |
|---|---|---|---|
| 6/30/2026 | Sell | $70.0 | $397,670 |
| 6/17/2026 | Sell | $61.2 | $611,880 |
| 6/16/2026 | Sell | $60.3 | $603,176 |
| 6/15/2026 | Sell | $60.7 | $336,212 |
| 5/19/2026 | Sell | $65.5 | $29,086 |
| 5/19/2026 | Sell | $65.5 | $13,036 |
| 2/18/2026 | Sell | $73.0 | $30,879 |
| 2/18/2026 | Sell | $73.0 | $13,140 |
| 1/20/2026 | Sell | $35.7 | $137,936 |
| 11/25/2025 | Sell | $54.3 | $119,796 |
| 11/25/2025 | Sell | $54.3 | $34,196 |
| 11/25/2025 | Sell | $54.3 | $62,802 |
| 9/9/2025 | Sell | $46.8 | $311,214 |
| 9/5/2025 | Sell | $38.9 | $256,850 |
| 9/4/2025 | Sell | $34.0 | $174,108 |
| 9/4/2025 | Sell | $34.0 | $57,692 |
| 9/2/2025 | Sell | $30.2 | $45,240 |
| 9/2/2025 | Sell | $30.1 | $14,599 |
| 8/19/2025 | Sell | $26.6 | $41,826 |
| 8/19/2025 | Sell | $26.6 | $17,975 |
| 8/19/2025 | Sell | $26.6 | $19,278 |
| 5/19/2025 | Sell | $0.7 | $15,549 |
| 5/19/2025 | Sell | $0.7 | $6,697 |
| 5/19/2025 | Sell | $0.7 | $7,177 |
| 2/19/2025 | Sell | $1.0 | $24,012 |
| 2/19/2025 | Sell | $1.0 | $11,150 |
| 2/19/2025 | Sell | $1.0 | $10,403 |
| 12/24/2024 | Sell | $0.9 | $14,738 |
| 12/23/2024 | Sell | $0.9 | $30,062 |
| 12/19/2024 | Sell | $0.9 | $48,048 |
| 12/18/2024 | Sell | $1.0 | $84,185 |
| 12/17/2024 | Sell | $1.0 | $47,465 |
| 11/19/2024 | Sell | $1.0 | $16,441 |
| 11/19/2024 | Sell | $1.0 | $6,471 |
| 11/19/2024 | Sell | $1.0 | $7,863 |
| 8/19/2024 | Sell | $1.3 | $19,048 |
| 8/19/2024 | Sell | $1.3 | $7,233 |
| 8/19/2024 | Sell | $1.3 | $8,788 |
All information without guarantee! No recommendation/consultation! © U.S. Securities and Exchange Commission (SEC)